Applied Therapeutics flags going concern amid steep cash burn, FDA CRL and legal costs

Quick brief - Applied Therapeutics, Inc. (NASDAQ: APLT)

Short summary: the company remains a clinical‑stage biotech with no product revenue, burning cash while defending lawsuits and addressing a November 2024 FDA Complete Response Letter and Warning Letter. Balance sheet weakened during H1 2025; management warns substantial doubt about going concern within 12 months.

Key facts & figures (as reported, unaudited)
* Cash and cash equivalents (June 30, 2025): $30,421 (thousands).
* Cash and cash equivalents (Dec 31, 2024): $79,398 (thousands).
* Net loss - six months ended June 30, 2025: $(43,155) (thousands).
* Net loss - three months ended June 30, 2025: $(21,330) (thousands).
* R&D expense - six months 2025: $17,760; six months 2024: $22,221 (thousands).
* G&A expense - six months 2025: $30,863; six months 2024: $19,646 (thousands).
* Change in fair value of warrant liabilities - six months 2025: +$4,541 (income); six months 2024: −$40,660 (loss) (thousands).
* Warrant liabilities decreased from $6,314 (Dec 31, 2024) to $1,773 (June 30, 2025) (thousands).
* Total assets - June 30, 2025: $37,342; Dec 31, 2024: $86,691 (thousands).
* Accumulated deficit: $(617,365) (thousands).
* Stockholders' equity - June 30, 2025: $17,438 (thousands) vs $57,006 at Dec 31, 2024.
* Operating cash flow - six months ended June 30, 2025: cash used $(48,977) (thousands).

What's happening inside Applied Therapeutics, Inc. (NASDAQ: APLT)
* Management is focused on responding to the FDA Complete Response Letter and Warning Letter tied to AT‑007 (govorestat) - this has driven higher legal and regulatory spend.
* The company presented ongoing CMT‑SORD (INSPIRE) data (12‑, 18‑ and 24‑month analyses) and is evaluating whether current data can support an NDA for that indication; a planned FDA meeting was referenced for Q3 2025.
* Cash fell sharply (≈$48.98M used in operating activities in H1 2025); management states substantial doubt about the company's ability to continue as a going concern without new financing.
* Corporate actions since period end: out‑licensing of AT‑001 to Biossil (July 31, 2025) - $1.0M upfront (subsequent event), potential future milestones/royalties.
* Litigation: securities class action consolidated and shareholder derivative suit pending; company is incurring significant legal costs and has disclosed material litigation risk.

Income statement - positives
* Research & development expense declined year‑over‑year (H1 2025 $17.8M vs H1 2024 $22.2M), primarily from lower clinical/pre‑clinical costs - suggests program progression/transition or some trial wind‑down.
* Warrant liability remeasurement produced net gains (+$4.5M H1 2025), improving reported other income and muting the operating loss impact on GAAP net loss for the period.
* Stock‑based compensation remained a modest non‑cash charge ($3.6M for six months), a controllable expense relative to cash burn.

Income statement - negatives
* G&A expense jumped materially (H1 2025 $30.9M vs H1 2024 $19.6M) - driven largely by legal/professional fees related to FDA interactions and securities litigation; this is non‑recurring but large and drains cash.
* No product revenue; total revenue $0 in H1 2025 (vs $0.3M prior year) - the Advanz service/license revenue has effectively run off.
* Large GAAP losses continue (H1 net loss $(43.2M)); operating cash burn is high and the balance sheet weakened meaningfully during the period.
* Balance sheet contraction: total assets down to $37.3M and stockholders' equity down to $17.4M - may limit borrowing or financing options without significant dilution.

Immediate issues and catalysts to monitor
* FDA interaction outcomes - remediation of CRL/Warning Letter and the Q3 2025 FDA meeting on potential CMT‑SORD NDA pathway are critical.
* Cash runway and financing: company flagged substantial doubt - watch for equity raises, ATM activity, partnerships or additional out‑licensing beyond the AT‑001 deal (July 31, 2025) to shore up liquidity.
* Litigation developments - motions to dismiss are pending in the consolidated securities action; outcomes will materially affect legal expense and risk.
* Clinical data from INSPIRE and any confirmatory studies - positive outcomes could re‑open regulatory and commercial opportunities; negative or inconclusive data will materially harm prospects.

Bottom line: Applied Therapeutics, Inc. (NASDAQ: APLT) remains a development‑stage biotech with clinical data in hand but no product revenue. The business is under stress from regulatory setbacks, rising G&A/legal costs and shrinking cash. Positive warrants remeasurement and a modest out‑license help, but the company needs financing or partner‑led funding to avoid dilution or program delays. Investors should focus on FDA remediation progress, near‑term cash strategy, and litigation outcomes.